Clinical trials: Cancer Patients and Physical Activity
Neuroblastoma, Rhabdomyosarcoma
Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors
The purpose of this study is to find the safe dose of nab-paclitaxel in children with solid tumors, and to see if it works to treat these solid tumors in children and young adults (in Phase 1 ≤ 18 years old and in Phase 2 ≤ 24…
- Conditions
- Neuroblastoma, Rhabdomyosarcoma, Ewing's Sarcoma, Ewing's Tumor
- Trial name
- NCT01962103
- Testing
- nab-paclitaxel
- Where
- 20 sites in United States, Canada and 5 more
- Volunteers
- 107 people
- Sponsor
- Celgene
Pediatric Cancer, Pediatric Cancer Patients
Real World Pediatric Oncology Rehabilitation in Italy ( ReWori )
This observational study aims to describe changes in the functional abilities of children, adolescents and young adults with cancer who are undergoing physiotherapy or neuropsychomotor rehabilitation.
- Conditions
- Pediatric Cancer, Pediatric Cancer Patients, Pediatric Oncology, Rehabilitation
- Trial name
- REWORI (NCT07368582)
- Testing
- Rehabilitation intervention
- Where
- 13 sites in Italy
- Volunteers
- 249 people
- Sponsor
- Associazione Italiana Ematologia Oncologia Pediatrica
Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer
A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification
This is a first-in-human (FIH), open-label, multicenter, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BGB-53038 as…
- Conditions
- Metastatic Solid Tumors, Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Colorectal Cancer, Advanced Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06585488
- Testing
- BGB-53038, Tislelizumab, Cetuximab
- Where
- 17 sites in United States, Australia and 3 more
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- BeOne Medicines
Acute Myeloid Leukemia, Multiple Myeloma
The Value of a Tailored-based, Exercise Program for Improving Quality of Life of Patients With Hematologic Malignancies: a Pilot Randomized Trial
This multicenter, prospective, pilot randomized controlled trial aims to evaluate the feasibility and preliminary efficacy of a 16-week structured exercise program (SEP) in patients with hematologic malignancies, including acute…
- Conditions
- Acute Myeloid Leukemia, Multiple Myeloma, Lymphoma
- Trial name
- Hematowellness (NCT07912684)
- Testing
- Structured Exercise Program (SEP)
- Where
- 3 sites in Italy
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Head and Neck Neoplasms
The Efficacy of Mouth Exercise in Oral Cancer Patients After Receiving Surgery
PURPOSE: The purpose of the study was to investigate the efficacy of mouth-opening training with follow-up on 1st、3rd、6th months for reducing postoperative trismus in patients with oral cancer.
- Trial name
- NCT05227807
- Testing
- mouth opening exercise, Usual care
- Volunteers
- 69 people
- Sponsor
- National Taipei University of Nursing and Health Sciences
Head and Neck Cancers, Trismus
Exercise Therapy and Jaw-Mobilizing Device for Trismus in Head and Neck Cancer Patients
This study evaluates the effects of exercise therapy combined with a jaw-mobilizing device on enhancing quality of life in head and neck cancer patients undergoing radiotherapy.
- Conditions
- Head and Neck Cancers, Trismus, Radiotherapy Side Effects
- Trial name
- ET-JMD for Tri (NCT06719388)
- Testing
- combination of exercise therapy and a jaw-mobilizing device, exercise therapy only
- Where
- Taiwan
- Volunteers
- 34 people
- Sponsor
- Taipei Medical University
Hepatocellular Carcinoma, Cholangiocarcinoma, Intrahepatic
Study of GNS561 in Patients With Liver Cancer
This is a first in human, open-label dose escalation study to investigate the safety, tolerability and pharmacokinetics of GNS561 in patients Primary and Secondary liver cancer
- Trial name
- NCT03316222
- Testing
- GNS561
- Where
- 5 sites in United States, Belgium and 1 more
- Volunteers
- 50 people
- Sponsor
- Genoscience Pharma
Head and Neck Cancer
Effect of Prehabilitation on Head and Neck Cancer Patients
The primary aim of the study is to investigate the feasibility of a prehabilitation program, which consists of a set of strategies including physical activity, nutritional support, and psychological counseling, carried out before…
- Trial name
- HNCANCERFIT (NCT06593639)
- Testing
- Prehabilitation before surgery, Prehabilitation before and during CRT
- Where
- 5 sites in Italy
- Volunteers
- 60 people
- Sponsor
- Laura Deborah Locati
Lymphoma, B-Cell, Lymphoma, Hodgkin
STAY-STRONG Study of Exercise Training During Chemotherapy
This study evaluates the effectiveness of a supervised progressive resistance training program in patients malignant lymphomas with the primary outcome being lean body mass.
- Conditions
- Lymphoma, B-Cell, Lymphoma, Hodgkin, Exercise, Body Composition
- Trial name
- STAY-STRONG (NCT05556239)
- Testing
- Resistance Exercise Training
- Where
- Denmark
- Volunteers
- 42 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Solid Tumors, Pancreatic Cancer
CTS2190 Phase I /II Clinical Study in Patients
This is a first in human study in patients with advanced or metastatic solid tumors. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific tumor types.
- Conditions
- Solid Tumors, Pancreatic Cancer, Non-small Cell Lung Cancer, Triple-negative Breast Cancer
- Trial name
- NCT06224387
- Testing
- CTS2190 capsules
- Where
- 2 sites in China
- Volunteers
- 224 people
- Sponsor
- CytosinLab Therapeutics Co., Ltd.
Breast Neoplasm
Combined Training Intervention for Women Who Underwent Primary Treatment for Breast Cancer
The aim of the present study is analyze the effects of combined training program (resistance and aerobics) in comparison with a non-training group on quality of life, as well as on neuromuscular and cardiorespiratory parameters…
- Trial name
- +Vida (NCT03124095)
- Testing
- Combined exercise Group
- Where
- Brazil
- Volunteers
- 30 people
- Sponsor
- Federal University of Pelotas
Melanoma (Skin)
A Phase I Trial of Normothermic Isolated Limb Infusion (ILI) With Melphalan Plus Buthionine Sulfoximine (BSO) in Patients With Locally Advanced Malignant Melanoma
RATIONALE: Buthionine sulfoximine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of tumor cells…
- Trial name
- NCT00661336
- Testing
- buthionine sulfoximine, melphalan, microarray analysis
- Where
- 2 sites in United States
- Sponsor
- Duke University
Advanced Solid Tumors
Safety and Activity of HF50 in Patients With Advanced Solid Tumors
A study to assess the safety, tolerability, and pharmacokinetics of HF50 in participants with advanced solid tumors.
- Trial name
- NCT07601334
- Testing
- HF50
- Where
- 2 sites in China
- Volunteers
- 45 people
- Sponsor
- HighField Biopharmaceuticals Corporation
Malignant Lymphoma
Lean Body Mass and Side Effects in Patients With Lymphoma
The primary purpose is to investigate the relationship between the dose of chemotherapeutic agents per kilogram of lean body mass (LBM) and the development of side effects induced by chemotherapy in patients with lymphoma.
- Trial name
- NCT04698616
- Where
- 2 sites in Denmark
- Volunteers
- 141 people
- Sponsor
- Jens Rikardt Andersen
Melanoma of Skin
APA (Adapted Physical Activity) for Patients With Advanced Melanoma
APA (adapted physical activity) for patients with advanced melanoma APA (adapted physical activity) for patients with advanced melanoma undergoing treatment: evaluation of a personalized program at the hospital Melanoma is a…
- Trial name
- APA-M (NCT07031830)
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Rouen
Non Hodgkin Lymphoma, Peripheral T Cell Lymphoma
A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies
ZX-101A-202 is a Phase I, open-label, multicenter study, a single-agent dose-escalation and dose-expansion study of ZX-101A. It is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacokinetics, efficacy and…
- Conditions
- Non Hodgkin Lymphoma, Peripheral T Cell Lymphoma, CLL/SLL
- Trial name
- NCT05269940
- Testing
- ZX-101A
- Where
- 3 sites in China
- Volunteers
- 40 people
- Sponsor
- Nanjing Zenshine Pharmaceuticals
Melanoma (Skin)
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic Malignant Melanoma
RATIONALE: Drugs used in chemotherapy, such as 17-N-allylamino-17-demethoxygeldanamycin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00104897
- Testing
- tanespimycin
- Where
- 2 sites in United Kingdom
- Volunteers
- 25 people
- Sponsor
- Cancer Research UK
Metastatic Melanoma, Brain Metastases
Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain
Phase II clinical trial, with two cohorts of patients included in parallel, all with melanoma BRAF mutated and brain metastases without previous local treatment in the brain.
- Trial name
- EBRAIN-MEL (NCT03898908)
- Testing
- encorafenib, binimetinib, Whole brain radiation therapy
- Where
- 21 sites in Spain
- Volunteers
- 48 people
- Sponsor
- Grupo Español Multidisciplinar de Melanoma
Retinoblastoma, Recurrent
Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma
Phase I study, single site, open label with dose escalation, for evaluate safety and the oncolitic Adenovirus VCN-01 activity in patients with refractory retinoblastoma.
- Trial name
- RTB (NCT03284268)
- Testing
- VCN-01
- Where
- Spain
- Volunteers
- 13 people
- Sponsor
- Fundació Sant Joan de Déu
Mycosis Fungoides
Pembrolizumab Administered Via the Sofusa® DoseConnect™ in Patients With Relapsed/Refractory Cutaneous T-cell Lymphoma.
In this pilot study, pembrolizumab will be administered via DoseConnect in patient with relapsed or refractory cutaneous T-cell lymphoma to assess through pharmacodynamic assessment in the tumor tissue to assess if lymphatic…
- Trial name
- NCT04118868
- Testing
- Pembrolizumab administered using the Sofusa® DoseConnect™
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Sorrento Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.